Drug recall · August 22, 2018
Valsartan recall
Why: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Valsartan, 160 mg, 30 tablets per bottle, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46256. NDC: 51655-460-52
- Lots / codes
Lot: UT48320002, exp 07/31/2018; Lot UT48320003, exp 05/31/2019
- Quantity
- 68 bottles
- Company
- Northwind Pharmaceuticals LLC, Indianapolis, IN
- Distribution
- Indiana
- Initiated
- July 18, 2018 · Voluntary: Firm initiated
- Classified
- August 15, 2018
- Reported
- August 22, 2018
- Ended
- March 25, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Valsartan
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.